

Federal Employee Program.

NK1 ANTAGONISTS

Akynzeo capsules (netupitant and palonosetron)
Akynzeo injection (fosnetupitant and palonosetron)
Cinvanti injection, Emend capsules, Emend oral suspension (aprepitant)
Emend injection, Focinvez* injection (fosaprepitant)
Varubi tablets (rolapitant)

Pre - PA Allowance Quantity

Medication	Quantity Limit
Akynzeo 300 mg/0.5 mg capsules	6 capsules per 90 days
Akynzeo 235 mg/0.25 mg injection	6 vials per 90 days
Cinvanti 130 mg injection	6 vials per 90 days
Aprepitant 40 mg	1 capsule per 90 days
Emend 80 mg	12 capsules per 90 days
Emend 125 mg	6 capsules per 90 days
Emend Bi-pack (contains two 80 mg caps)	6 packs per 90 days
Emend Tri-pack (contains one 125 mg and two 80	6 packs per 90 days
mg)	
Emend 125 mg suspension	6 kits per 90 days
Emend 150 mg injection	6 vials per 90 days
Focinvez 150 mg injection	6 vials per 90 days
Varubi 90 mg tablets	12 tablets per 90 days

^{**}Quantities are based 2 chemotherapy treatments per month

Prior-Approval Requirements

Prior authorization is not required if prescribed by an oncologist and/or the member has paid pharmacy claims for an oncology medication(s) in the past 6 months

Akynzeo capsules and injection Diagnosis

Patient must have the following:

- 1. Prevention of acute or delayed nausea and vomiting
 - a. 18 years of age or older
 - b. Undergoing chemotherapy for cancer
 - i. Akynzeo injection only: chemotherapy is highly emetogenic
 - c. Administered with dexamethasone
 - d. Absence of severe renal impairment (eGFR less than 30 ml/min/1.73m²) or end state renal disease (ESRD)
 - e. Absence of severe hepatic impairment (Child-Pugh Class C)

Emend oral suspension, Emend injection, and Focinvez injection

^{*}Product covered on the medical benefit only



Federal Employee Program.

NK1 ANTAGONISTS

Akynzeo capsules (netupitant and palonosetron)
Akynzeo injection (fosnetupitant and palonosetron)
Cinvanti injection, Emend capsules, Emend oral suspension (aprepitant)
Emend injection, Focinvez* injection (fosaprepitant)
Varubi tablets (rolapitant)

*Product covered on the medical benefit only

Diagnosis

Patient must have the following:

- 1. Prevention of acute or delayed nausea and vomiting
 - a. 6 months of age or older
 - b. Weight ≥ 6 kg
 - c. Undergoing chemotherapy for cancer
 - d. Used in combination with other antiemetic

Emend capsules Diagnoses

Patient must have **ONE** of the following:

- 1. Prevention of acute or delayed nausea and vomiting
 - a. 12 years of age or older
 - b. Undergoing chemotherapy for cancer
 - c. Used in combination with other antiemetic
- 2. Postoperative nausea and vomiting (PONV)
 - a. 18 years of age or older

Cinvanti injection Diagnosis

Patient must have the following:

- 1. Prevention of acute or delayed nausea and vomiting
 - a. 18 years of age or older
 - b. Undergoing chemotherapy for cancer
 - c. Used in combination with other antiemetic

Varubi tablets Diagnosis

Patient must have the following:

- 1. Prevention of delayed nausea and vomiting
 - a. 18 years of age or older
 - b. Undergoing chemotherapy for cancer
 - c. Administered with dexamethasone and a 5-HT3 receptor antagonist
 - d. Absence of severe hepatic impairment (Child-Pugh Class C)



Federal Employee Program.

NK1 ANTAGONISTS

Akynzeo capsules (netupitant and palonosetron)
Akynzeo injection (fosnetupitant and palonosetron)
Cinvanti injection, Emend capsules, Emend oral suspension (aprepitant)
Emend injection, Focinvez* injection (fosaprepitant)
Varubi tablets (rolapitant)

Prior - Approval LimitsQuantity

Postoperative nausea and vomiting

Medication	Quantity Limit
Aprepitant 40 mg	5 capsules per 90 days

Acute or Delayed nausea and vomiting

Medication	Quantity Limit
Akynzeo 300 mg/0.5mg capsules	12 capsules per 90 days OR
Akynzeo 235 mg/0.25 mg injection	12 vials per 90 days OR
Cinvanti 130 mg injection	12 vials per 90 days OR
Emend 80 mg	48 capsules per 90 days OR
Emend 125 mg	12 capsules per 90 days OR
Emend Bi-pack (contains two 80 mg caps)	24 packs per 90 days OR
Emend Tri-pack (contains one 125 mg and two 80	12 packs per 90 days OR
mg)	
Emend 125 mg suspension	18 kits per 90 days OR
Emend 150 mg injection	12 vials per 90 days OR
Focinvez 150 mg injection	12 vials per 90 days OR
Varubi 90 mg tablets	24 tablets per 90 days OR

Duration 12 months

Prior – Approval Renewal Requirements

Same as above

Prior - Approval Renewal Limits

Same as above

^{*}Product covered on the medical benefit only